Definium Therapeutics, Inc. (MMQ0)
XFRA 
Summary
MMQ0 Chart
Definium Therapeutics' DT120 Meets Phase III Goals in GAD Study
Definium Therapeutics NASDAQ: DFTX reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The company said the trial met its primary endpoint and all key secondary endpoints, showing rapid and durable improvements in anxiety symptoms through 12 weeks.
Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript
Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript
Definium Therapeutics, Inc. (MMQ0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Definium Therapeutics, Inc. ever had a stock split?
Definium Therapeutics, Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Robert Barrow CEO | XFRA Exchange | CA24477V1058 ISIN |
| US Country | 106 Employees | - Last Dividend | 29 Aug 2022 Last Split | - IPO Date |
Overview
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies aimed at addressing brain health disorders. The organization is dedicated to advancing novel treatment options for conditions that significantly impact mental well-being. Based in New York, New York, Definium Therapeutics integrates cutting-edge research with rigorous clinical trials to bring forth products that have the potential to improve the quality of life for individuals experiencing various mental health challenges.
Products and Services
- MM120
- MM402
MM120 is currently in phase 3 clinical trials and is designed to address two significant mental health conditions: generalized anxiety disorder and attention deficit hyperactivity disorder (ADHD). By focusing on these prevalent disorders, the company aims to provide effective treatment options that can aid individuals suffering from anxiety-related issues and attention deficits, enhancing their daily functioning and overall quality of life.
MM402 is an R-enantiomer of 3,4-methylenedioxymethamphetamine, which is undergoing phase I clinical trials. This product is specially developed to target the core symptoms associated with autism spectrum disorder (ASD). By exploring innovative approaches to treating ASD, Definium Therapeutics is positioning itself at the forefront of research aimed at improving therapies that address the unique challenges faced by individuals with autism, thus promoting better behavioral and social outcomes.
